Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 4, 2017

View Archived Issues

PepVax initiates in vivo efficacy study for lead candidate PVX-009

Heptares initiates phase I study of selective muscarinic M4 receptor agonist HTL-0016878

Oncodesign acquires Bertin Pharma's pharmaceutical and biotech services business

EMD Serono details discovery of BTK inhibitor now in clinical development

Second-generation RET inhibitors developed for irritable bowel syndrome

EMBL, Savira patent compounds for treating influenza

MediWound reports new phase II data on EscharEx

Inventisbio describes new indoleamine 2,3-dioxygenase 1 inhibitors

High mobility group protein B1 inhibitors disclosed by Kyungpook National University

Global Blood Therapeutics divulges novel EHMT2 inhibitors

Sprint Bioscience discloses novel PIK3C3 and autophagy inhibitors

Protein kinase inhibitors reported at Korea Institute of Science and Technology, DGMIF

Debiopharm, Evotec describe new IDH1, IDH2 inhibitors

APRIL has prognostic significance in acute heart failure

Midatech submits CTA to begin first-in-human study of MTD-201

Spyryx Biosciences initiates phase II study of SPX-101 in cystic fibrosis

INN-108 receives U.S. orphan drug status for pediatric ulcerative colitis

U.S. Traumakine BLA submission can follow completion of European and Japanese phase III studies

FDA grants tentative approval to Sanofi's Admelog

FDA confers orphan drug status on VXM-01 for malignant glioma

Venetoclax given FDA orphan drug designation for mantle cell lymphoma

Collaboration discovers enhanced GABA(A) receptor subunit alpha-6 ligands

FDA approves Mylotarg for AML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
At AACR: Epigenetic fingerprints in metastases track tumor origin
BioWorld
When a tumor migrates and colonizes another tissue or organ, it can be identified as a metastasis, but its origin is not always clear. Now, a study based on...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...